SI1729773T1 - Monohidroklorid 8-hidroksi-5-((hidroksi-2-(((1r)-2-(4-metoksifenil)-1- metiletil)amino)(etil-2(1h)-kinolinona - Google Patents

Monohidroklorid 8-hidroksi-5-((hidroksi-2-(((1r)-2-(4-metoksifenil)-1- metiletil)amino)(etil-2(1h)-kinolinona

Info

Publication number
SI1729773T1
SI1729773T1 SI200530320T SI200530320T SI1729773T1 SI 1729773 T1 SI1729773 T1 SI 1729773T1 SI 200530320 T SI200530320 T SI 200530320T SI 200530320 T SI200530320 T SI 200530320T SI 1729773 T1 SI1729773 T1 SI 1729773T1
Authority
SI
Slovenia
Prior art keywords
hydroxy
áethyl
methylethyl
methoxyphenyl
amino
Prior art date
Application number
SI200530320T
Other languages
English (en)
Inventor
Fausto Pivetti
Roberto Pighi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1729773(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of SI1729773T1 publication Critical patent/SI1729773T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200530320T 2004-03-24 2005-03-24 Monohidroklorid 8-hidroksi-5-((hidroksi-2-(((1r)-2-(4-metoksifenil)-1- metiletil)amino)(etil-2(1h)-kinolinona SI1729773T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
EP05730069A EP1729773B1 (en) 2004-03-24 2005-03-24 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
SI1729773T1 true SI1729773T1 (sl) 2008-10-31

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530320T SI1729773T1 (sl) 2004-03-24 2005-03-24 Monohidroklorid 8-hidroksi-5-((hidroksi-2-(((1r)-2-(4-metoksifenil)-1- metiletil)amino)(etil-2(1h)-kinolinona

Country Status (30)

Country Link
US (1) US20070197586A1 (sl)
EP (1) EP1729773B1 (sl)
JP (1) JP2007530489A (sl)
KR (1) KR20070001946A (sl)
CN (2) CN1929840B (sl)
AR (1) AR048339A1 (sl)
AT (1) ATE399552T1 (sl)
AU (1) AU2005224032A1 (sl)
BR (1) BRPI0508213A (sl)
CA (1) CA2560650A1 (sl)
CY (1) CY1108323T1 (sl)
DE (1) DE602005007871D1 (sl)
DK (1) DK1729773T3 (sl)
EA (1) EA010128B1 (sl)
ES (1) ES2309739T3 (sl)
HR (1) HRP20080495T3 (sl)
IL (1) IL178227A0 (sl)
MA (1) MA28549B1 (sl)
MX (1) MXPA06010515A (sl)
NO (1) NO20064274L (sl)
NZ (1) NZ550010A (sl)
PE (1) PE20060159A1 (sl)
PL (1) PL1729773T3 (sl)
PT (1) PT1729773E (sl)
RS (1) RS50602B (sl)
SI (1) SI1729773T1 (sl)
TN (1) TNSN06249A1 (sl)
UA (1) UA86221C2 (sl)
WO (1) WO2005089760A1 (sl)
ZA (1) ZA200607907B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride

Also Published As

Publication number Publication date
US20070197586A1 (en) 2007-08-23
WO2005089760A1 (en) 2005-09-29
EP1729773A1 (en) 2006-12-13
NZ550010A (en) 2010-08-27
CN1929840B (zh) 2010-12-08
ZA200607907B (en) 2008-04-30
EA200601531A1 (ru) 2007-04-27
BRPI0508213A (pt) 2007-07-17
HRP20080495T3 (en) 2008-11-30
AR048339A1 (es) 2006-04-19
MXPA06010515A (es) 2007-03-30
EA010128B1 (ru) 2008-06-30
CN101812017A (zh) 2010-08-25
NO20064274L (no) 2006-10-13
DK1729773T3 (da) 2008-10-20
PL1729773T3 (pl) 2008-12-31
KR20070001946A (ko) 2007-01-04
UA86221C2 (en) 2009-04-10
CA2560650A1 (en) 2005-09-29
PE20060159A1 (es) 2006-04-04
CY1108323T1 (el) 2014-02-12
TNSN06249A1 (en) 2007-12-03
MA28549B1 (fr) 2007-04-03
PT1729773E (pt) 2008-09-29
IL178227A0 (en) 2006-12-31
EP1729773B1 (en) 2008-07-02
CN1929840A (zh) 2007-03-14
DE602005007871D1 (de) 2008-08-14
ATE399552T1 (de) 2008-07-15
ES2309739T3 (es) 2008-12-16
AU2005224032A1 (en) 2005-09-29
RS50602B (sr) 2010-05-07
JP2007530489A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
GB2399362B (en) Crosslinking delaying agents for acid fluids
IL177052A0 (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
IL162253A0 (en) Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
IL181619A0 (en) Asymmetric spring components and innersprings for one-sided mattresses
EP1791941A4 (en) UNCHLORINATED, CONCENTRATED ALL-IN-ONE-ACID SUBSTANCE AND ITS USE
IL178164A0 (en) Single crystals and methods for fabricating same
PT1757582E (pt) Arilalquilaminas e processo para a sua produção
IL186928A (en) A process for making a lipid-polar preparation and using it
PL1922309T3 (pl) Pochodne n-fenylo-2-pirymidynoaminy oraz sposób ich otrzymywania
EP1794533A4 (en) HEAT EXCHANGERS AND MANUFACTURING METHOD THEREFOR
IL172802A0 (en) Aztreonam l-lysine and methods for the preparation thereof
SI1729773T1 (sl) Monohidroklorid 8-hidroksi-5-((hidroksi-2-(((1r)-2-(4-metoksifenil)-1- metiletil)amino)(etil-2(1h)-kinolinona
EP1939170A4 (en) PROCESS FOR PREPARING GABAPENTINE HYDROCHLORIDE
EP1874722A4 (en) HYDROXAMIC ACID DERIVATIVES AND PROCESSES FOR PREPARING THE SAME
SI1753720T1 (sl) Postopek za pripravo perindoprila in njegovih soli
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
HK1113079A1 (en) Orally administrable antimalarial combined preparation and preparation process thereof
ZA200405245B (en) Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
IL191052A0 (en) Process for the preparation of tamsulosin and related compounds
GB0519891D0 (en) Pharmaceutically acceptable salts and hydrates
GB0518135D0 (en) Sertraline acid addition salt,its preparation and its use in the preparation of sertraline hydrochloride form II
HK1117848A1 (en) Assay method for human orotate phosphoribosyltransferase protein
GB0408156D0 (en) Process and compounds
GB0420607D0 (en) Amino acid
IL165456A0 (en) Pharm